StockNews.AI
ELDN
StockNews.AI
1 min

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

1. Eledon will present at the International Xenotransplantation Association Congress. 2. Talk focuses on immunosuppression and CD40 Ligand pathway blockade. 3. The session is led by Dr. Steve Perrin, enhancing corporate visibility. 4. Tegoprubart could revolutionize treatments for kidney transplantation and ALS. 5. Company’s lead product targets a significant biological pathway.

3m saved
Insight
Article

FAQ

Why Bullish?

The presentation at a key congress may raise investor interest, similar to past events for biotechnology firms that unveiled new research pipelines or partnerships.

How important is it?

The presentation highlights Eledon's strategies and research advances, which can positively influence market perception and stock performance due to the relevance of the topic in current therapeutic dialogues.

Why Short Term?

The upcoming event date signifies immediate potential for stock movement as news circulates and investor sentiments shift towards the anticipated results and developments.

Related Companies

VRTXALNYCRIS
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland. Details are as follows: Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How Far do We Need to Go?Lecture Title: 201.2 Anti-CD154 Pathway BlockadeDate: Wednesday, October 1, 2025Time: 10:30 a.m. – 12:00 p.m. CET *CD154 is also known as CD40L or CD40 Ligand About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com. Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@cglife.com Source: Eledon Pharmaceuticals

Related News